| 王莉,王磊,迟磊.帕金森病病人血清 CCL11、sTREM2与病情进展及认知障碍的相关性[J].安徽医药,2025,29(10):2079-2083. |
| 帕金森病病人血清 CCL11、sTREM2与病情进展及认知障碍的相关性 |
| Correlation between serum CCL11, sTREM2 and disease progression, cognitive dysfunction in Parkinson disease patients |
| |
| DOI：10.3969/j.issn.1009-6469.2025.10.034 |
| 中文关键词: 帕金森病 CC趋化因子配体 11 可溶性髓样细胞触发受体 2 认知功能障碍 蒙特利尔认知评估量表 |
| 英文关键词: Parkinson disease CC chemokine ligand 11 Soluble triggering receptor expressed on myeloid cells 2 Cognitive dys-function Montreal cognitive assessment |
| 基金项目: |
|
| 摘要点击次数: 34 |
| 全文下载次数: 44 |
| 中文摘要: |
| 目的探究帕金森病病人血清中 CC趋化因子配体 11(CCL11)、可溶性髓样细胞触发受体 2(sTREM2)与病情进展以及发生认知功能障碍的相关性。方法该研究回顾性选取 2021年 1月至 2023年 6月在张家口宣钢医院神经内科就诊的 168例帕金森病病人为研究对象记为帕金森病组，并根据蒙特利尔认知评估量表( MoCA评分)分为认知功能正常组( 76例)和认知功能障碍组( 92例)；同时选取同期在该院体检的 120例健康志愿者作为健康组。采用酶联免疫吸附分析( ELISA)检测所有受试者血清中 CCL11、sTREM2表达水平；采用多因素 logistic回归分析方法分析各因素对帕金森病病人发生认知功能障碍的影响；采用受试者操作特征曲线( ROC曲线)分别评估血清中 CCL11、sTREM2表达水平单独及联合预测对帕金森病病人发生认知功能障碍的诊断价值。结果帕金森病组病人血清中 CCL11［( 72.58±20.64)μg/L，(55.37±16.74)μg/L］、 sTREM2［( 387.24± 107.35)ng/L，(296.38±86.28)ng/L］表达水平显著高于健康组(P<0.05)，并且随着病情严重程度的增加，血清中 CCL11、sTREM2表达水平逐渐升高(P<0.05)；认知功能正常组与认知功能障碍组在 MoCA评分［(27.91±2.83)分，(15.77±1.76)分］、帕金森综合评分量表第三部分( UPDRS Ⅲ)评分［( 25.32±2.77)分，(28.88±2.96)分］、 CCL11［( 61.48±17.35)μg/L，(81.75±21.37)μg/L］与 sTREM2［( 343.37±72.35)ng/L，(423.48±117.32)ng/L］表达水平上均差异有统计学意义( P<0.05)； CCL11表达水平、 sTREM2表达水平、 UPDRSⅢ评分是帕金森病病人发生认知功能障碍的独立危险因素( P<0.05)而 MoCA是帕金森病病人发生认知功能障碍的独立保护因素( P<0.05)； CCL11、sTREM2单独诊断帕金森病病人发生认知功能，障碍的 AUC 95%CI分别为 0.84(0.78，0.89)、 0.87(0.81，0.92)；二者联合诊断帕金森病病人发生认知功能障碍的 AUC 95%CI为 0.94(0.89，0.97)，优于血清 CCL11、 sTREM2各自单独诊断( Z=3.34、3.13，P=0.001、0.002)。结论随着帕金森病病人病情严重程度的增加，血清中 CCL11、 sTREM2表达水平逐渐升高， CCL11、sTREM2联合诊断帕金森病病人发生认知功能障碍具有较高价值，可作为早期诊断指标。 |
| 英文摘要: |
| Objective To investigate the correlation between serum levels of CC chemokine ligand 11 (CCL11) and soluble triggeringreceptor expressed on myeloid cells 2 (sTREM2) in Parkinson disease (PD) patients with disease progression and cognitive dysfunction.Methods This study retrospectively selected 168 PD patients who visited Department of Neurology, Xuangang Hospital of Zhangjiak-ou from January 2021 to June 2023 as the study subjects and recorded them as the PD group, and according to the Montreal cognitiveassessment (MoCA) scoring results, these patients were assigned into a normal cognitive function group (n=76) and a cognitive dysfunc-tion group (n=92); meanwhile, 120 healthy volunteers who underwent physical examinations in the same hospital were selected as thehealthy control group. Enzyme linked immunosorbent assay (ELISA) was applied to detect the expression levels of CCL11 and sTREM2in the serum of all subjects; multivariate Logistic regression analysis was applied to analyze the impact of various factors on the occur-rence of cognitive dysfunction in PD patients; receiver operating characteristic (ROC) curve was applied to evaluate the diagnostic val-ues of serum CCL11 and sTREM2 expression levels individually and in combination for cognitive dysfunction in PD patients.Results The expression levels of CCL11 [(72.58±20.64) μg/L, (55.37±16.74) μg/L] and sTREM2 [(387.24±107.35) ng/L, (296.38±86.28) ng/L]in the serum of patients in PD group were obviously higher than those in control group (P<0.05), and as the severity of the disease in-creased, the expression levels of CCL11 and sTREM2 in the serum gradually increased (P<0.05). There were statistically significant dif-ferences in MoCA score [(27.91±2.83) points, (15.77±1.76) points], unified Parkinson disease rating scale Ⅲ (UPDRS Ⅲ) score[(25.32±2.77) points, (28.88±2.96) points], CCL11 [(61.48±17.35) μg/L, (81.75±21.37) μg/L] and sTREM2 [(343.37±72.35) ng/L,(423.48±117.32) ng/L] expression levels between normal cognitive function group and cognitive dysfunction group (P<0.05). The ex-pression levels of CCL11, sTREM2, and UPDRSⅢ score were independent risk factors for cognitive dysfunction in PD patients (P< 0.05), while MoCA was an independent protective factor for cognitive dysfunction in PD patients (P<0.05). The AUC 95%CI of cogni-tive dysfunction in PD patients diagnosed with CCL11 or sTREM2 alone were 0.84 (0.78, 0.89) and 0.87 (0.81, 0.92), respectively; theAUC 95%CI for the combined diagnosis of cognitive dysfunction in PD patients was 0.94 (0.89, 0.97), which was superior to the individ-ual diagnosis of serum CCL11 or sTREM2 (Z=3.34, 3.13; P=0.001, 0.002).Conclusions As the severity of PD patients increases, theexpression levels of CCL11 and sTREM2 in serum gradually increase. Combination of CCL11 and sTREM2 has high value in diagnos-ing cognitive dysfunction in PD patients, which can be used as an early diagnostic indicator. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
